Ovarian Cancer | Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

Research To Practice | Oncology Videos

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics:

• Introduction (0:00)
• Case: A woman in her late 60s with recurrent serous papillary adenocarcinoma of the fallopian tube with a germline BRCA1 mutation — Yanjun Ma, MD (5:24)
• Case: A woman in her mid-60s with Stage IIIC fallopian tube carcinoma with no deleterious mutations — Lyndsay J Willmott, MD (9:11)
• Case: A woman in her late 70s with ovarian cancer (OC) and a germline BRCA2 mutation — Shachar Peles, MD (14:22)
• Case: A woman in her mid-40s with Stage IIIC serous OC and a germline BRCA1 mutation — Dr Wilmott (17:06)
• PARP inhibitor maintenance therapy (23:32)
• Case: A woman in her late 60s with Stage IV OC and a germline BRCA1 mutation — Laurie Matt-Amaral, MD, MPH (39:43)
• Case: A woman in her late 70s with Stage IIIC OC with a germline BRCA mutation who develops anemia on olaparib — Sulfi Ibrahim, MD (43:55)
• Niraparib-associated thrombocytopenia and surgical procedures — Heidi E Godoy, DO (47:14)
• Case: A woman in her mid-70s with recurrent OC and a germline and somatic BRCA2 mutation — Dana M Chase, MD (50:42)
• Novel strategies with PARP inhibitors in OC (53:38)

CME information and select publications